

# Trends

## ① Patent cliffs

Copaxone, Viagra, Strattera, Sustiva and Viread lost patent protection in 2017, and are beginning to see generic competition. Expect to see revenue losses for these products in 2018.

## ③ Drug pricing


US President Donald Trump accused the pharmaceutical industry of "getting away with murder" in reference to drug prices. The administration took no major action against drug companies in the past year.

## ② Opioid crisis

41 US state attorneys general announced lawsuits against opioid manufacturers in response to rampant opioid addiction in the country. The CDC estimates the prescription opioid abuse epidemic has an economic burden of \$78.5B a year.

33 small molecules

13 biologics



CDMOs increase their serialization capabilities

# 20

## YEAR IN

First FDA approvals of chimeric antigen receptor T cell therapy, also known as CAR-T

release with higher biologic production

## 46 drugs

were approved by the FDA in 2017. Oncology was the most prevalent therapeutic area, with 12 drugs approved for oncology applications. Five biosimilars were also approved.

# New drugs

# Capacities

29 expansions



26 expansions



## 35 CDMOs

announced or completed facility expansions in 2017, increasing their small molecule, biologic, and drug product manufacturing capabilities and capacities.


4 expansions



in anticipation of the US Drug Security Quality Act  
18 site and company acquisitions also increased CDMO capacities and capabilities

# 2017

## ANNUAL REVIEW



## Over 60

mergers and acquisitions were announced in 2017. QuintilesIMS also rebranded to IQVIA in late 2017.

